The FIRST team is excited to announce that the FIRST trial has reached 42% of it's total enrolment target in December.
The FIRST trial aims assess whether surgical correction of the impingement morphology (arthroscopic osteochondroplasty) with or without labral repair, in adults aged 18 to 50 diagnosed with non-arthritic Femoroacetabular Impingement, provides decreased pain at 12 months compared to arthroscopic lavage of the hip joint as measured by the Visual Analog Scale.
The FIRST-EPIC prospective cohort study has also reached 35% of it's total enrolment target in December.
The primary and secondary objectives of FIRST will be evaluated within the embedded prospective cohort (FIRST-EPIC). The data from this group will also be used to evaluate effectiveness (in addition to efficacy) of osteochondroplasty and other standard of care treatments for FAI in patients with potentially distinct prognostic factors, cost-effectiveness of the interventions and the feasibility of data collection for a potential large prospective database pertaining to FAI.